Stocks · News reference
This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Analysts upgraded Sagimet, Figure, Illumina, Martin Marietta and Waters, raising price targets and improving ratings.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
3 Crypto-Exposed Stocks Riding the Institutional Crypto Wave
Wall Street's cryptocurrency environment has improved with growing institutional participation through regulated ETFs, regulatory progress via the CLARITY Act, and stablecoin adoption. Bitcoin ETFs saw strong inflows in August-September 2026, while three crypto-related stocks—Figure Technology, Chime Financial, and Paymentus—are highlighted as investment opportunities. However, cryptocurrencies remain vulnerable to interest rate changes and Federal Reserve policy shifts.
Figure Technology Solutions to Participate in Upcoming Investor Conferences
Figure Technology Solutions announced its participation in two upcoming investor conferences: a presentation at the Goldman Sachs Communacopia + Technology Conference on September 10th and attendance at the FT Partners Fintech Conference on September 15th. The company continues to lead the blockchain-native capital marketplace space with over $30 billion in originated loans and operates multiple platforms including Figure Connect and Democratized Prime.
This Copart Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday
Analysts upgraded Copart, Orchestra BioMed, Illumina, Martin Marietta Materials and Waters, raising their price targets.
This Meta Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Analysts upgraded SFNC, OBIO, and more.
Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now
Tandem Diabetes (TNDM) is positioned for growth with its expanding product roadmap including the Mobi tubeless pump, new CGM integrations, and AIDANET closed-loop program. The company's pay-as-you-go reimbursement model aims to lower upfront barriers and boost recurring supply revenue. However, macroeconomic pressures, reimbursement sensitivity, competitive threats, and the impact of GLP-1 drugs on insulin therapy demand pose significant headwinds to sustained profitability.